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The efficacy of cognitive behavioural therapy for adults with ADHD: A 
systematic review and meta-analysis of randomised controlled trials 
 
Abstract 
 
Objective: To systematically review published RCTs of cognitive behavioural therapy 
(CBT) for adult ADHD and establish the effectiveness of CBT reducing ADHD symptoms. 
Method: A systematic review of nine RCTs and two subsequent meta-analyses of eight 
of the studies were conducted. Results: Just nine studies were identified, of generally 
good quality but with some limitations. Four trials (total N = 160) compared CBT to 
waiting list controls and three trials (total N = 191) compared CBT to appropriate active 
control groups. Meta-analyses showed that CBT was superior to waiting list with a 
moderate to large effect size (standardised mean difference [SMD] = 0.76, 95% CI 0.21 
to 1.31, p = .006) and superior to active control groups with a small to moderate effect 
size (SMD = 0.43, 95% CI 0.14 to 0.71, p = .004). Conclusion: These results give 
support to the efficacy of CBT in combination with medication in reducing symptoms of 
ADHD immediately post-intervention. 
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Background 
 
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition 
characterised by three core symptoms: inattention, hyperactivity and impulsivity 
(American Psychiatric Association [APA], 2013) and affects around 4-5% of the adult 
population (Kessler et al., 2006). ADHD is increasingly recognised as lifelong for the 
majority with symptoms persisting into adulthood for two-thirds of people (Wilens, 
Faraone, & Biederman, 2004). Commonly it is the hyperactive element that is thought to 
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desist, but inattention and impulsivity remain (Advokat, Martino, Hill, & Gouvier, 2007). 
There are high rates of psychiatric comorbidity (e.g. depression, substance misuse; 70-
75% comorbidity (Wilens, Biederman, & Spencer, 2002)) and poorer outcomes (e.g. 
more car accidents, higher divorce rates, and more frequent job changes than adults 
without ADHD (Faraone et al., 2000; Wilens et al., 2004) especially for those diagnosed 
in adulthood (Klein et al., 2012). 
 
The first-line treatment for ADHD is pharmacotherapy (National Institute for Health and 
Care Excellence [NICE], 2013), with most research on adults focussing on medication 
efficacy (Faraone & Glatt, 2010; Spencer et al., 2005; Wilens, Spencer, & Biederman, 
2001). Pharmacotherapy has been found to be effective for some; however, 20-50% of 
adults are either not suitable for medication, are classed as ‘non-responders’ or are 
unable to tolerate the side-effects (Wilens et al., 2001). Even for those for whom 
medication is effective, symptoms have only been reduced by up to 30% (Wilens et al., 
2001). Less is known about how well medication treats the functional impairment - such 
as time management and organisation - and arguably it neglects the wider social and 
emotional relationships, and quality of life difficulties that people experience (Biederman 
et al., 1993; Faraone et al., 2000; Wilens et al., 2004).  
 
Psychotherapy is much less researched for this population although it is becoming more 
widely used as an adjunct or alternative to pharmacotherapy, with NICE guidelines now 
recommending a multimodal approach to treatment (NICE, 2013). Cognitive Behavioural 
Therapy (CBT) is a group of interventions that comprise a number of basic features, 
including psychoeducation, cognitive restructuring and skills training, with the aim of 
changing cognitions and behaviour and ultimately reducing psychological distress. It is 
important to acknowledge that variation exists between different types of CBT and its 
application between clinicians, but all share the aforementioned core features and 
theoretical basis. To date the evidence base for the use of CBT with people with ADHD is 
scant but arguments for its use are beginning to emerge.  
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Based on the premise that ADHD has a neurobiological basis, Safren, Sprich, Chulvick, 
and Otto (2004) have proposed a CBT model of ADHD, which highlights the importance 
of functional impairments in ADHD (such as working memory, inhibitory control and 
sustained attention) underpinning the core symptoms of inattention, hyperactivity and 
impulsivity. They argue that such impairments hinder learning or adapting coping 
strategies, resulting in continued difficulties. Adults may have lived with the condition 
untreated for many years and a potential history of failure or negative experiences may 
affect cognitions. This may in turn affect motivation, reducing the likelihood of learning 
better coping. Learning compensatory skills may be intrinsic to reducing functional 
impairment and CBT, by targeting negative cognitions, may also serve to impact on the 
emotional aspects of ADHD (Safren et al., 2004). 
 
CBT is gathering evidence as a credible treatment for ADHD with the emergence of 
reviews of psychological treatments for ADHD (Knouse, Cooper-Vince, Sprich, & Safren, 
2008; Weiss et al., 2008), highlighting a number of uncontrolled CBT studies (Rostain & 
Ramsay, 2006; Solanto, Marks, Mitchell, Wasserstein, & Kofman, 2008; Virta et al., 
2008) as showing promising results in terms of ADHD symptom reduction. However, 
these studies are limited by small samples sizes and lack of control groups and in recent 
years randomised controlled trials (RCTs) have begun to emerge (e.g. Emilsson et al., 
2011; Safren et al., 2010; Stevenson, Whitmont, Bornholt, Livesey, & Stevenson, 2002). 
One review (Knouse & Safren, 2010) estimated effect sizes from a range of controlled 
studies under the CBT umbrella suggesting moderate to large effects of treatment; 
however, a pooled effect size is also presented which does not weight the studies by 
sample size. A further review (Mongia & Hechtman, 2012) also looked at RCTs from 
2004 onwards. However, this review was not systematic, rendering it not replicable and 
potentially biased. It also included a study that was not an RCT (Bramham et al., 2009). 
To date there is no published systematically conducted meta-analysis of studies of the 
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efficacy of CBT for ADHD. In addition, existing reviews have not systematically assessed 
the quality of existing studies.  
 
 
The aim of the review is to investigate the efficacy of CBT for adults with ADHD. The 
objectives were: 1) To systematically identify and assess the quality of RCTs 
investigating the efficacy of CBT for adults with ADHD; 2) To use meta-analysis to 
determine whether CBT was better than either waiting list control or an alternative non-
CBT control in reducing symptoms of ADHD; 3) To make recommendations for future 
practice and research, based on the findings of the review.  
 
Method  
Meta-analysis 
Studies investigating the efficacy of CBT for adult ADHD are limited by small sample 
sizes; therefore pooling the results of the studies gave the review higher statistical 
power than any of the single studies. Meta-analysis allows pooling of data with variation 
in sample sizes accounted for and therefore allows conclusions to be drawn or at least 
guidance of discussion from the data already available. Pooling results in meta-analyses 
however, can also accentuate the risk of bias. The results from meta-analyses can also 
be influenced significantly by the inclusion of poor quality studies, although this is often 
overlooked by researchers and potentially results in biased reviews (Jüni et al., 2001). 
Meta-analyses may not always be reliable or valid; in some cases meta-analyses using 
the same studies have found differing results (Green & Taplin, 2003). To address such 
shortcomings in meta-analyses of RCTs specifically, the QUOROM Statement (Quality of 
Reporting of Meta-Analyses) was developed (Moher et al., 1999) and updated with the 
PRISMA statement (Preferred Reporting Items for Systematic reviews and Meta-
Analyses) (Moher et al., 2009). These guidelines acknowledged the poor quality of 
reviews with the aim of improving the quality of future reporting. This review therefore 
presents a meta-analysis of RCTs and pilot RCTs and is guided by the PRISMA statement 
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(Moher et al., 2009), to address biases and methodological flaws apparent in many 
existing reviews. 
 
Criteria for Inclusion of Studies 
Types of Studies 
RCTs or pilot RCTs reporting a comparison of CBT with an adequate control group were 
included if they were published in a peer-reviewed journal. Quality of studies was not 
used as an excluding criteria. The acronym PICO was developed to provide consistency 
in identifying studies for reviews of clinical research (Stillwell, Fineout-Overholt, Melnyk, 
& Williamson, 2010) where: (P) patient population, (I) intervention, (C) comparison 
group, and (O) outcome. PICO was adopted and exhibited by the following criteria: 
 
Types of Participants 
All studies included participants with ADHD as defined by any diagnostic criteria. 
Symptom severity, longevity of symptoms, the presence of comorbid psychiatric 
conditions and gender did not exclude studies from selection. Age was an exclusion 
criteria with only studies using adult participants (over 18 years) being selected.  
 
Types of Interventions and Comparison Group 
The review only included studies reporting the use of CBT or therapies under the CBT 
umbrella (such as meta-cognitive therapy which is a group CBT approach) as the 
experimental condition and a control condition of either wait list (waiting list for CBT 
treatment) or active (alternative treatment to CBT). Although a priori criteria initially 
defined the control conditions as ‘inactive (wait list or treatment as usual)’ or ‘active’ 
(alternative treatment to CBT), all papers with an inactive control were found to use wait 
list (rather than ‘treatment as usual’).  The active control treatment was defined by each 
study individually, but was some alternative treatment to CBT, such as relaxation (see 
results for more details). Studies were not excluded based on whether medication was 
used in either condition.  
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Types of Outcome Measures 
Studies that included results from post-treatment continuous outcome measures 
assessing ADHD symptom severity were included. This allowed for comparison between 
treatment and control groups to determine response to CBT. Due to variability in types 
of ADHD symptom scales used across studies, any ADHD rating scale was acceptable if it 
was based on the DSM diagnostic criteria. Studies should have reported means 
(standardised or un-standardised) and standard deviations (SD) in order to meet the 
criteria for meta-analysis. It was hoped that effect sizes for improvement of inattention, 
hyperactivity, and impulsivity could have been examined separately, but this was not 
possible as included papers often did not report each subscale independently.  
 
Information Sources and Search Strategy 
A systematic search of the following databases was conducted using an a-priori defined 
search string: MEDLINE, PsycINFO, CINAHL and EMBASE. The following headings and 
keywords were used: (a) “cognitive behavioural therapy” OR “CBT” OR “cognitive 
therapy” OR “cognitive behavio* therap*”; (b) “attention deficit hyperactivity disorder” 
OR “ADHD” OR “attention deficit disorder”; (C) “randomised controlled trial” OR “RCT” 
OR “random* control* trial”. Searches were limited to studies using adult participants 
(over 18 years) that were published in the English Language. 
 
Study Selection 
Figure 1 outlines the initial identification of 70 studies and the process through which the 
final eight studies were selected for inclusion and analysis.  
 
Meta-analysis Procedure 
Two meta-analyses aimed to address the questions of whether CBT was (1) better than 
waiting list control or (2) better than an alternative non-CBT control in reducing 
symptoms of ADHD. In studies with active controls, participants would have received 
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more clinical contact (regardless of the content of that contact) than those on waiting 
lists, and there may therefore be distinct results between waiting list and active controls. 
The meta-analyses were conducted using the software Review Manager 5 (Cochrane, 
2008). Two meta-analyses were conducted on eight selected RCTs: five studies 
compared CBT with waiting list controls (CBT-waitlist) and three studies compared CBT 
with an active control group (CBT-active). Two RCTs (Pettersson, Söderström, Edlund-
Söderström, & Nilsson, 2014; Virta et al., 2010) included each had two treatment groups 
and one control group. In these cases the active CBT treatment group and inactive 
waiting list control groups were included in the analysis. Decisions on which ADHD 
outcome measure to use in the meta-analysis were made on a case-by-case basis 
depending on the measures used or reported in each study. Where available, 
independent evaluator assessments were chosen over self-reported measures. When 
only self-reported measures were employed these were used. However, sensitivity 
analyses were conducted to ascertain whether pooled results were biased by inclusion of 
studies that relied on self-report assessment: independent evaluation of post-treatment 
symptoms would be considered the ‘gold standard’ and self-report measures could be 
biased by participants not being blinded to their treatment allocation. Additional 
sensitivity analyses were undertaken to determine whether pooled results were biased 
by inclusion of studies appraised as being of lower quality (described further under 
‘Quality Assessment and Risk of Bias’).  
 
It was intended that the meta-analysis would look at outcome measures post-therapy 
and at follow-up. However, due to an absence of follow-up data within the included 
studies it was only possible to conduct a meta-analysis on the post-therapy data and not 
at follow-up points.  
 
Effect sizes of ADHD symptoms were estimated by standardised mean difference (SMD; 
Hedges’ adjusted g), weighted by sample size using a random effects model in CBT-
waitlist (to take both within- and between-study variation into account) and a fixed 
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effect model in CBT-active (to take within-study variation into account). The reason for a 
fixed effects model to analyse the CBT-active control studies was that there were too few 
(three) studies to use a random effects model, whereas the five studies (CBT-waitlist) 
could be analysed using the preferred random effects model. A confidence interval of 
95% was used. Effect sizes of 0.2, 0.5, and 0.8 are deemed small, moderate and large 
respectively (Cohen, 1988).   
 
Heterogeneity 
Tests of heterogeneity should be used in meta-analyses to ascertain whether the trials 
are similar enough in terms of methodology, participants and interventions employed. 
Statistical heterogeneity should also be assessed to ensure that trials are suitable to pool 
the results and this is measured by the I2 statistic where 0% is low heterogeneity and 
100% is high heterogeneity. I2 scores of 85% or higher suggest that a meta-analysis is 
not appropriate. 
 
 
 
Results 
 
Results of the Review 
Data Extraction and Synthesis 
For each study the following data was extracted: authors; year or publication; location; 
study aims; sample size and composition; inclusion/exclusion criteria; how participants 
were diagnosed; concealment of allocation; level of blinding; intention to treat (ITT); 
participant withdrawal; data collection; measures used and their outcomes; and key 
findings.  
Participants 
The studies included were conducted across seven countries. They had a total of 386 
participants, 173 male and 213 female. The overall age range was difficult to establish 
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as most studies gave only an average age. Length of time since diagnosis was not given 
by any studies.  
 
Quality Assessment and Risk of Bias 
In order to assess the reliability of study results, it is necessary to assess the quality and 
risk of bias in each of the studies included in the analysis. A number of measures has 
been designed for use in RCTs. However, the use of scales to assess bias is a contentious 
issue due to a lack of evidence for their accurate assessment of validity and their use of 
summary scores (Jüni et al., 2001). Some argue against the use of such scales that 
create summary scores (Higgins et al., 2011; Jüni et al., 2001), in favour of tools 
designed to guide your assessment of risk of bias; therefore a quality assessment tool 
based on Brown and colleagues (2013), along with recommendations by Higgins and 
colleagues (2011), and without the use of summary scores, was used as a guide to 
structure the assessment of quality. Publication bias was not examined due to there 
being too few studies to include.  
 
CBT-waitlist: The results of the quality assessment are shown in Table 1. Only one out 
of the five studies described the method of randomisation and reported having concealed 
allocation of treatment group. Arguably this is a fundamental feature of RCTs and future 
research should aim to describe the method in more detail. All five studies reported 
inclusion and exclusion criteria and information on baseline comparability between the 
treatment and control groups. It was notable that all studies stipulated that participants 
on medication should maintain their dose during the study. All reported at least some 
participants not adhering to this but only four studies reported on how the effects of this 
were accounted for by way of statistical analysis. No studies were excluded based on 
their quality assessment; however, a sensitivity analysis was planned as a second stage 
to the quality assessment, to determine whether pooled meta-analytic results were 
biased by inclusion of studies with lower quality ratings. Specifically, sensitivity analysis 
was planned to test whether pooled estimates were robust to inclusion of the CBT-
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waitlist study meeting fewest quality-assessment criteria (Virta et al., 2010). Sensitivity 
analysis outcomes are reported under ‘Results from the Meta-analysis’.  
 
CBT-active: The quality assessment of the studies comparing CBT with an active control 
group is shown in Table 2. One out of the four studies described the randomisation 
process; however, no studies reported concealment of allocation to treatment group. All 
four studies reported baseline characteristics and achieved comparability, reported 
inclusion criteria and had blinded evaluators. Of the three studies where all participants 
were on medication, one study described all participants maintaining their dose and two 
studies reported that some of their participants changed dose during the study; two of 
these three studies described how they accounted for these medication changes. Only 
one of the four studies asked their participants to refrain from any other treatments 
during the study. As described for CBT-waitlist studies, sensitivity analysis was planned 
to assess the impact of including lower-quality studies; specifically, to test whether 
pooled estimates were robust to inclusion of the CBT-active study meeting fewest 
quality-assessment criteria (Weiss et al., 2012). Sensitivity analysis outcomes are 
reported under ‘Results from the Meta-analysis’. 
 
 
 
Additional relevant information from studies  
Some studies reported additional information, which may be related to the efficacy of 
CBT within their trials.  
CBT-waitlist: Table 3 shows the five studies comparing CBT with waiting list control 
groups. CBT was the treatment group in all studies, although some CBT variations were 
included, namely cognitive remediation and meta-cognitive therapy, due to the similarity 
in content. The studies used a range of outcome measures. However, the only consistent 
measure was of ADHD symptom ratings, therefore subsequent analyses focussed only on 
ADHD symptoms. All five studies found CBT to be superior to waiting list controls (with 
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the majority of participants in each group on medication) and the three studies that 
collected follow-up data found that gains were maintained post treatment from two-
months up to one-year (Emilsson et al., 2011; Pettersson et al., 2014; Stevenson et al., 
2002). Improvements in comorbid symptoms of anxiety and depression were found in 
some studies (Emilsson et al., 2011; Safren et al., 2005) but not others (Stevenson et 
al., 2002) and improvements were also found in organisation, self-esteem and anger 
management (Stevenson et al., 2002). 
 
One study (Emilsson et al., 2011) gave additional individual coaching between the group 
CBT sessions (by psychology undergraduates trained by the group facilitators) with the 
aim of helping participants to transfer skills learned to their daily lives. Another study 
(Stevenson et al., 2002) used support people (a minimum of one telephone call between 
sessions) for participants, to help with appointment reminders, note-taking, and any 
difficulties encountered during the study. The supporters were either nominated by the 
participant or were a psychology student, and met with participants between group 
sessions. Contact time with clinicians and supporters was not controlled for. Two studies 
also offered additional optional sessions on relaxation and sleep (Pettersson et al., 2014) 
or memory, impulsivity, anger management or an extra session on topics previously 
covered (Virta et al., 2010). 
 
CBT-active: The above studies are limited by the treatment group receiving more 
clinician attention than the control group, so non-specific treatment effects have not 
been controlled for. Improving on this, Table 4 shows four studies comparing CBT with 
an active control group, for example relaxation with educational support, supportive 
therapy and psychoeducation or placebo medication. Three out of the four studies used 
independent evaluators post-treatment and only two collected follow-up data; therefore 
only immediately post-intervention outcomes were analysed.  
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One study (Estrada et al., 2013) delivered one of the CBT sessions with a family member 
of each group participant present. Another (Safren et al., 2010) offered additional 
optional sessions on either procrastinating, a session with a family member or booster 
sessions on topics already covered. The only study that investigated comorbid symptoms 
of anxiety and depression found no significant improvements (Solanto et al., 2010).  
 
The above studies employed a range of group and individual control treatments and 
found mixed results; two studies found CBT to be superior to relaxation with educational 
support (Safren et al., 2010) and supportive psychotherapy (Solanto et al., 2010) and 
one study found a negative effect so that psychoeducation was more effective than CBT 
(although not significantly) (Estrada et al., 2013). Follow-up data were only collected by 
one study where treatments gains were maintained up to nine months post-treatment 
(Safren et al., 2010). 
 
Results from the Meta-analysis 
 
CBT-waitlist: Table 5 shows summary statistics for the range of ADHD symptom scales 
scores comparing post-intervention ADHD symptom measures between treatment and 
control groups showing that people receiving CBT were more likely to see reduced 
symptom severity than those in the waiting list control group (n = 5; SMD = 0.76; 95% 
CI 0.21 to 1.31, p = .006; random effects model).  The plot in Figure 2 shows an 
advantage for treatment over control with all studies’ point estimates and the diamond 
showing the pooled effect appearing to the left of the axis. Chi square test of 
heterogeneity looks for whether the differences between the studies’ results could be 
due to chance. I2 values between 40 and 84% call for a random effect method due to 
high heterogeneity. Heterogeneity was calculated as I2 = 63% suggesting moderate 
heterogeneity. Effect sizes (SMDs; Hedges’ adjusted g) for each individual study are also 
reported in Figure 2 and range between 0.20 and 1.75, suggesting small to large effect 
sizes.  
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Sensitivity analysis was conducted to ascertain whether pooled estimates were robust to 
the inclusion of studies that only employed self-report measures. The advantage for 
treatment over control remained after removal of two studies that relied on self-report 
(Pettersson et al., 2014; Stevenson et al., 2002): n = 3; SMD = 0.65; 95% CI 0.20 to 
1.09; p = .004. Among the remaining studies, heterogeneity reduced to I2 = 2%. A 
second sensitivity analysis was conducted to test for robustness to the inclusion of 
studies with lower methodological quality (as assessed against applied criteria; Table 1). 
The advantage for treatment over control remained after removal of the lowest quality 
study (Virta et al., 2010): n = 4; SMD = 0.88; 95% CI 0.53 to 1.24; p < .001; I2 = 
66%. 
 
CBT-active: After the exclusion of one study for employing CBT in both treatment 
conditions (Weiss et al., 2012), three studies remained eligible for meta-analysis. Table 
5 shows summary statistics for the range of ADHD symptom scales scores comparing 
post-intervention ADHD symptom scores between CBT treatment and active control 
groups showing that people receiving CBT were more likely to see reduced symptom 
severity than those in the active control group (n = 3; SMD = 0.43; 95% CI 0.14 to 
0.71, p = .004; fixed effects model).  The plot in Figure 3 shows an advantage for 
treatment over control with two out of three studies’ point estimates, and the diamond 
showing the pooled effect, appearing to the right of the axis. Heterogeneity was 
calculated as I2 = 31% suggesting low heterogeneity. Effect sizes for the individual 
studies are also reported in Table 5, ranging between -0.13 and 0.57, suggesting a 
range between a negative effect and medium effect. 
 
Sensitivity analysis was conducted to ascertain whether pooled estimates were robust to 
the inclusion of studies that only employed self-report measures. The advantage for 
treatment over control remained after removal of one study that relied on self-report 
(Estrada et al., 2013): n = 2; SMD = 0.54; 95% CI 0.22 to 0.86; p < .001; I2 = 0%. 
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The CBT-active study with the lowest quality rating (Weiss et al., 2012) was excluded 
from the pooled estimate reported above; consequently, the second planned sensitivity 
analysis – to test for robustness of results to inclusion of the lowest quality study – was 
not conducted.  
 
 
Discussion 
 
Nine RCTs examining the effect of CBT on ADHD symptoms in adults were identified in 
the review, with eight of these studies being eligible for the meta-analyses. Two meta-
analyses were conducted due to differences in control groups; CBT-waitlist compared 
CBT with waiting list controls and CBT-active compared CBT with an appropriate, active 
control group. Methodological differences between studies prevented further analyses of 
measures such as quality of life, comorbidities and maintenance of treatment gains at 
follow-up. Results from the meta-analyses show a benefit of CBT over waiting list 
controls and active controls in the reduction of ADHD symptoms immediately post-
treatment. A number of recommendations for future research and clinical practice can be 
drawn from the review.  
 
The study quality assessment highlighted that the studies were generally of good quality 
with most of the quality criteria met or partially met. Significantly, a number of studies 
did not show that they were truly random. This may have biased their results and, in 
turn, the findings of the current review, although sensitivity analyses showed that the 
results of the meta-analyses were robust to the removal of lower quality studies. Due to 
the nature of treatment vs. control groups, blinding of those giving treatment and 
participants is not possible, which may be a further limitation. With the exception of one 
study (Estrada et al., 2013) which found a negative effect, all the studies showed a 
positive effect of CBT over the control condition. However, to what extent this effect is 
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influenced by publication bias is unclear as negative results are less likely to have been 
published. 
 
The results from the CBT-waitlist meta-analysis were limited by studies using an inactive 
control group, reducing the experimental rigour (MacCoon et al., 2012). Some argue 
that shared effects of therapy need to be controlled for in psychological therapy research 
(Jensen, Weersing, Hoagwood, & Goldman, 2005) but others argue that the 
methodologies of pharmaceutical trials should not be translated to psychological 
therapies as shared effects are part of therapy and should not be controlled for (Bentall, 
2009). Several studies did not employ independently assessed post-treatment measures, 
which could impact on the results, as self-reported measures are limited by participants 
not being blinded as to whether they received the intervention, further highlighting the 
need for active control groups. The CBT-active analyses went some way in improving 
these limitations by employing active control conditions such as psychoeducation or 
supportive therapy groups. These results can counteract the argument that the group 
environment or amount of attention given to those receiving the active treatment 
intervention is the reason for treatment effects. However, only a small number of studies 
were available for this analysis, one of which did not use independent assessors of post-
treatment outcomes. 
 
The majority of participants included in the review were taking ADHD medication during 
the trial. Although many studies requested that those on medication remained on a 
stable dose, not all participants adhered to this and not all studies monitored this. 
However, those that had a combination of people on and off medication (Stevenson et 
al., 2002; Virta et al., 2010) did ensure that there were no between-group differences at 
baseline. Some studies did not ask their participants to refrain from concurrent 
psychological treatment and did not collect data on this (e.g. Virta et al., 2010); 
therefore treatment effects may not be attributable to CBT in such cases. Most studies 
reported only the overall ADHD symptom score rather than subscales of attention, 
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hyperactivity and impulsivity, potentially masking the effects of CBT on each individual 
core symptom and preventing further subscale analyses. Researcher or therapist 
allegiance was not discussed in any study, which can be a significant source of bias 
within studies (Jüni et al., 2001), although in most cases where independent evaluators 
were utilised, they were blinded to treatment condition reducing the likelihood of bias. 
 
A more thorough meta-analysis of outcomes other than ADHD symptoms was not 
possible due to insufficient or inconsistent outcome data across studies on measures 
such as quality of life, with only three of the included studies collecting this data across 
both analyses (Estrada et al., 2013; Pettersson et al., 2014; Virta et al., 2010) and the 
measures utilised being too dissimilar. Although some studies collected data on 
outcomes of comorbidities such as anxiety and depression (Emilsson et al., 2011; 
Estrada et al., 2013; Pettersson et al., 2014; Safren et al., 2005; Solanto et al., 2010; 
Virta et al., 2010) and some found significant reductions in symptoms (Emilsson et al., 
2011; Safren et al., 2005), there was not sufficient data or sufficient similarities between 
measures employed for this to be analysed further. As inattention could be a symptom of 
depression and / or anxiety, it may be useful to conduct more detailed research into the 
relationship between ADHD symptoms and comorbid anxiety and depression where 
either are a target of CBT interventions. An analysis of follow-up data was not possible 
either due to a lack of data, with only a few studies collecting adequate data (Emilsson 
et al., 2011; Pettersson et al., 2014; Safren et al., 2010) or for not collecting data on 
both treatment and control groups (Stevenson et al., 2002).  
 
There was insufficient data on functional impairments to evaluate this by meta-analyses, 
making it difficult to comment on the theory by Safren et al. (2004) that the core 
symptoms of inattention, hyperactivity and impulsivity are underpinned by functional 
impairments in ADHD (such as working memory, inhibitory control and sustained 
attention). The reduction in symptoms seen in the reviewed studies arguably lends 
support for the theory, although whether this is via learning compensatory strategies, by 
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targeting negative cognitions or by other means is unclear. Various authors have 
speculated that differing aspects of CBT are intrinsic to symptom reduction, for example, 
discouraging avoidance and procrastination (Bramham et al., 2009), employing cognitive 
strategies to improve self-esteem through identifying, challenging and replacing negative 
thoughts (Stevenson et al., 2002), behavioural skills training to develop effective coping 
strategies (Rostain & Ramsay, 2006) and understanding the neurobiological basis of 
ADHD aiding restoration of self-esteem (Safren et al., 2004). However, as yet it is 
unclear whether a particular aspect of CBT is paramount or whether it is the broad range 
of cognitions, emotions and behaviours that CBT targets that makes it effective. 
Conclusions regarding this cannot be drawn from the current review as detailed analysis 
of the CBT components and their individual outcomes was not researched in any study.  
 
Despite the limitations of the extant literature, this review adds to the growing evidence-
base for the effectiveness of CBT in reducing the symptoms of ADHD and gives rise to 
recommendations for future research, both in terms of design and questions to be 
addressed. To improve the rigour of future research, it is recommended that studies use 
and clearly report true randomisation, with active control groups and discussion of 
researcher and / or therapist allegiance. Ideally, independently assessed post-treatment 
measures would be employed, both after treatment and at follow-up points to establish 
the sustainability of any treatment effects. More attention should be paid to the role of 
medication and / or other psychological treatments utilised by study participants, for 
example either by asking participants to refrain or by reporting data on additional 
treatments to improve the reliability of attributing change to active CBT interventions. 
Studies measuring ADHD symptoms may benefit from measuring and reporting 
subscales of attention, hyperactivity and impulsivity to determine which, if any, are most 
improved as a result of CBT. Additional measures of functional impairments and 
outcomes such as quality of life and comorbid mental health difficulties may also be 
helpful.  
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Future research could aim to address a number of specific questions to contribute to the 
evidence base for CBT for ADHD. These include whether group or individual therapy is 
most useful, what the optimal length and number of sessions is and what time period of 
treatment is most efficacious. More detailed research into the efficacy of the various 
components of CBT will help us to understand the process by which CBT helps to reduce 
ADHD symptoms. Further research is also needed to build on the results from Weiss et 
al. (2012) suggesting that medication did not provide any additional benefit to CBT, an 
important implication for those who choose not to take medication, or for those whom 
medication is ineffective or intolerable. Ideally, for conclusions to be drawn, future 
studies would employ three conditions: CBT; active control group; TAU. Future reviews 
should also seek to synthesise data from CBT groups compared with other active 
therapeutic approaches unrelated to CBT in order to determine whether CBT is superior 
to other therapies.  
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Figure 1: Flow chart for identifying relevant studies 
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Table 1: Quality assessment table for studies comparing CBT ± medication with waiting list ± medication (CBT-waitlist) 
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Table 2: Quality assessment table for studies comparing CBT ± medication with active control ± medication (CBT-active) 
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Table 3: Study characteristics table for studies comparing CBT ± medication with waiting list ± medication (CBT-wait) 
First author, 
year, 
location 
          Assessment 
Design Participants CBT arm Control arm CBT content Measure Assessor Follow-up? 
Emilsson, 
2011,  
Iceland 
RCT N = 54  
M (SD) age = 
33.88 (11.47)  
68% female 
Group CBT + 
medication (n = 27) 
15 twice weekly 
sessions of 90 
minutes* 
Waitlist + 
medication (n = 27) 
Neurocognitive (attention, 
memory, impulse control and 
planning), problem solving, 
emotional control, pro-social skills, 
critical reasoning 
K-SADS Independent Yes 
Pettersson, 
2014, 
Sweden 
RCT N = 32  
M (SD) age = 
36.34 ()  
69% female 
Group therapist-led 
internet CBT (iCBT) ± 
medication (n = 14)  
10 weekly sessions of 
3 hours 
Waitlist ± 
medication (n = 18) 
Behaviour analysis, mindfulness & 
acceptance, time management, 
gauging attention span, reducing 
distractors, organisation & 
planning, problem solving, 
behaviour activation, cognitive 
restructuring, anger control 
ADHD-CSS Self Yes (CBT 
only) 
Safren,  
2005,                 
USA 
RCT N = 31  
M (SD) age = 
45.5 (10.6)  
55% female 
Individual CBT + 
medication (n = 16) 
7 core sessions (no 
further information 
provided) 
Waitlist + 
medication (n = 15) 
Psychoeducation, organisation & 
planning, problem solving, coping 
with distractibility, cognitive 
restructuring 
ADHD -RS Independent No 
Stevenson, 
2002, 
Australia 
RCT N = 43  
M (SD) age = 
35.86 (9.43)  
33% female 
Group Cognitive 
Remediation (CRP) ± 
medication (n = 22) 
8 weekly sessions of 2 
hours** 
Waitlist ± 
medication (n = 21) 
Motivation, concentration, 
listening, impulsivity organisation, 
anger management, self-esteem 
ADHD 
Checklist 
Self Yes (CBT 
only) 
Virta,     
2010,  
Finland 
Pilot  
RCT 
N = 20  
M (SD) age = 
36.1 (N.R.)  
65% female 
Individual CBT ± 
medication (n = 10) 
10 weekly sessions of 
60 minutes 
Waitlist ± 
medication (n = 10) 
Goals and symptoms, attention al 
control, motivation and initiation 
of activities, organisation & 
planning, stress management & 
relaxation, self-esteem 
ASRS Independent 
& self 
No 
* coaching provided  ** weekly telephone call provided   KSADS = The Kiddie-Schedule for Affective Disorders and Schizophrenia ADHD section; ADHD-CSS = ADHD Current Symptom Scale; 
ADHD-RS = ADHD Rating Scale; ASRS = Adult ADHD Self-Report Scale, N.R. = not reported 
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Table 4: Study characteristics table for studies comparing CBT ± medication with active control ± medication (CBT-active) 
First author, 
year,             Assessment 
location Design Participants CBT arm Control arm CBT content Control content Measure Assessor Follow-up? 
Estrada, 
2013,  
Spain 
Pilot  
RCT 
N = 32 
M (SD) age = 
39.5 (7.5) 
53% female 
Group CBT + 
medication (n = 
17) 
12 weekly 
sessions of 2 
hours* 
Psycho-
education + 
medication 
(n = 15) 
Psychoeducation, 
organisation & planning, 
problem solving, reducing 
distractibility, 
environmental modification, 
behavioural analysis, 
cognititve restructuring, 
procrastination 
Psychoeducation (no 
homework or practice 
and no treatment 
component) 
ADHD-RS Self No 
Safren,  
2010,  
USA 
RCT N = 86 
M (SD) age = 
43.16 (11.29) 
44% female 
Individual CBT + 
medication (n = 
43) 
12 weekly 
sessions of 50 
minutes 
Relaxation + 
medication 
(n = 43) 
Psychoeducation, 
organisation & planning, 
problem solving, reducing 
distractibility, cognitive 
restructuring 
Progressive muscle 
relaxation, 
psychoeducation, 
supportive 
psychotherapy 
ADHD -RS Independent Yes 
Solanto, 
2010,  
USA 
RCT N = 88 
M (SD) age = 
41.69 (11.84) 
66% female 
Group Meta-
cognitive therapy 
(MCT) + 
medication (n = 
45) 
12 weekly 
sessions of 2 
hours 
Supportive 
therapy + 
medication 
(n = 43) 
Task-management, 
organisation, planning 
Psychoeducation, goal-
setting, support and 
encouragement 
AISRS Independent No 
* one session with a family member 
ADHD-RS = ADHD Rating Scale; AISRS = Adult ADHD Investigator Symptom Rating Scale.  
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Figure 2: Forest Plot of comparison: CBT  versus Waitlist , outcome: ADHD symptoms 
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Figure 3: Forest Plot of comparison: CBT+med versus active control+med, outcome: ADHD symptoms 
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